Open AccessCiglitazone ameliorates lung inflammation by modulating the inhibitor κB protein kinase/nuclear factor-κB pathway after hemorrhagic shock
Author(s) -
Ranjit S. Chima,
Paul W. Hake,
Giovanna Piraino,
Prajakta Mangeshkar,
Alvin Denenberg,
Basilia Zingarelli
Publication year - 2008
Publication title -
critical care medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.002
H-Index - 271
eISSN - 1530-0293
pISSN - 0090-3493
DOI - 10.1097/ccm.0b013e318187810e
Subject(s) - ciglitazone , medicine , endocrinology , inflammation , pharmacology , peroxisome proliferator activated receptor , receptor
Peroxisome proliferator-activated receptor-gamma is a ligand-activated transcription factor. Ciglitazone, a peroxisome proliferator-activated receptor-gamma ligand, has been shown to provide beneficial effects in experimental models of sepsis and ischemia/reperfusion injury. We investigated the effects of ciglitazone on lung inflammation after severe hemorrhage.